V. M. Naegelen

Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

J. Schellens, M. Scheulen, V. Diéras, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

F. Rojo, J. Albanell, J. Soria, 2012, Clinical Cancer Research.

Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials

F. Gleeson, E. Shochat, F. Kraeber-Bodéré, 2012, The Journal of Nuclear Medicine.

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012, Clinical Cancer Research.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .